Eritoran tetrasodium

Eritoran tetrasodium (pronunciation: eh-rih-TOHR-an te-truh-SOH-dee-uhm) is a synthetic compound with potential immunomodulating and antiviral activities.

Etymology

The name "Eritoran" is derived from the Greek words "eri" meaning "early" and "toran" meaning "to break". The "tetrasodium" part of the name refers to the four sodium atoms in the compound.

Definition

Eritoran tetrasodium, also known as E5564, is a Lipid A antagonist and Toll-like receptor 4 (TLR4) inhibitor. It was developed by Eisai Co. for the treatment of severe sepsis.

Pharmacology

Upon administration, eritoran tetrasodium binds to and inhibits the activation of TLR4, which may result in the inhibition of the release of pro-inflammatory cytokines and may protect against cytokine-mediated organ damage in sepsis patients.

Clinical Trials

Eritoran has been tested in clinical trials for its potential to treat severe sepsis and septic shock. However, it failed to show a significant effect on 28-day mortality in a Phase III clinical trial. More recently, it has been studied for potential use in the treatment of viral infections, including SARS-CoV-2, the virus that causes COVID-19.

Related Terms

• Lipid A
• Toll-like receptor 4
• Sepsis
• Cytokines
• SARS-CoV-2
• COVID-19

See Also

• Eisai Co.
• Immunomodulator
• Antiviral drug

External links

• Medical encyclopedia article on Eritoran tetrasodium
• Wikipedia's article - Eritoran tetrasodium

This WikiMD dictionary article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski